147 related articles for article (PubMed ID: 33462345)
1. Cost-effectiveness of CYP2C19-guided antiplatelet therapy for acute coronary syndromes in Singapore.
Kim JH; Tan DS; Chan MYY
Pharmacogenomics J; 2021 Apr; 21(2):243-250. PubMed ID: 33462345
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of CYP2C19-guided antiplatelet therapy in patients with acute coronary syndrome and percutaneous coronary intervention informed by real-world data.
Limdi NA; Cavallari LH; Lee CR; Hillegass WB; Holmes AM; Skaar TC; Pisu M; Dillon C; Beitelshees AL; Empey PE; Duarte JD; Diaby V; Gong Y; Johnson JA; Graves J; Garbett S; Zhou Z; Peterson JF;
Pharmacogenomics J; 2020 Oct; 20(5):724-735. PubMed ID: 32042096
[TBL] [Abstract][Full Text] [Related]
3. Cost-Effectiveness of Strategies to Personalize the Selection of P2Y
Kim K; Touchette DR; Cavallari LH; Ardati AK; DiDomenico RJ
Cardiovasc Drugs Ther; 2019 Oct; 33(5):533-546. PubMed ID: 31367811
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of cytochrome P450 2C19 *2 genotype-guided selection of clopidogrel or ticagrelor in Chinese patients with acute coronary syndrome.
Wang Y; Yan BP; Liew D; Lee VWY
Pharmacogenomics J; 2018 Jan; 18(1):113-120. PubMed ID: 28117433
[TBL] [Abstract][Full Text] [Related]
5. CYP2C19 LOF and GOF-Guided Antiplatelet Therapy in Patients with Acute Coronary Syndrome: A Cost-Effectiveness Analysis.
Jiang M; You JH
Cardiovasc Drugs Ther; 2017 Feb; 31(1):39-49. PubMed ID: 27924429
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of
Fu Y; Zhang XY; Qin SB; Nie XY; Shi LW; Shao H; Liu J
Pharmacogenomics; 2020 Jan; 21(1):33-42. PubMed ID: 31849282
[No Abstract] [Full Text] [Related]
7. Economic Evaluations of CYP2C19 Genotype-Guided Antiplatelet Therapy Compared to the Universal Use of Antiplatelets in Patients With Acute Coronary Syndrome: A Systematic Review.
AlMukdad S; Elewa H; Al-Badriyeh D
J Cardiovasc Pharmacol Ther; 2020 May; 25(3):201-211. PubMed ID: 32027168
[TBL] [Abstract][Full Text] [Related]
8. CYP2C19 genotype plus platelet reactivity-guided antiplatelet therapy in acute coronary syndrome patients: a decision analysis.
Jiang M; You JH
Pharmacogenet Genomics; 2015 Dec; 25(12):609-17. PubMed ID: 26398625
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of genotype-guided and dual antiplatelet therapies in acute coronary syndrome.
Kazi DS; Garber AM; Shah RU; Dudley RA; Mell MW; Rhee C; Moshkevich S; Boothroyd DB; Owens DK; Hlatky MA
Ann Intern Med; 2014 Feb; 160(4):221-32. PubMed ID: 24727840
[TBL] [Abstract][Full Text] [Related]
10. Lifetime cost-effectiveness analysis of ticagrelor in patients with acute coronary syndromes based on the PLATO trial: a Singapore healthcare perspective.
Chin CT; Mellstrom C; Chua TS; Matchar DB
Singapore Med J; 2013 Mar; 54(3):169-75. PubMed ID: 23546032
[TBL] [Abstract][Full Text] [Related]
11. An Evaluation of the Cost-effectiveness of Comprehensive MTM Integrated with Point-of-Care Phenotypic and Genetic Testing for U.S. Elderly Patients After Percutaneous Coronary Intervention.
Okere AN; Ezendu K; Berthe A; Diaby V
J Manag Care Spec Pharm; 2018 Feb; 24(2):142-152. PubMed ID: 29384027
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of universal and platelet reactivity assay-driven antiplatelet therapy in acute coronary syndrome.
Coleman CI; Limone BL
Am J Cardiol; 2013 Aug; 112(3):355-62. PubMed ID: 23631863
[TBL] [Abstract][Full Text] [Related]
13. Short- and long-term cost-effectiveness analysis of CYP2C19 genotype-guided therapy, universal clopidogrel, versus universal ticagrelor in post-percutaneous coronary intervention patients in Qatar.
AlMukdad S; Elewa H; Arafa S; Al-Badriyeh D
Int J Cardiol; 2021 May; 331():27-34. PubMed ID: 33535078
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness analysis of CYP2C19 genotype-guided antiplatelet therapy for patients with acute minor ischemic stroke and high-risk transient ischemic attack in China.
Zhang Z; Bao Y; Gu Y; Zhang M; Li X
Br J Clin Pharmacol; 2024 Feb; 90(2):483-492. PubMed ID: 37795861
[TBL] [Abstract][Full Text] [Related]
15. Review of pharmacoeconomic evaluation of genotype-guided antiplatelet therapy.
Jiang M; You JH
Expert Opin Pharmacother; 2015 Apr; 16(5):771-9. PubMed ID: 25660101
[TBL] [Abstract][Full Text] [Related]
16. Cost-Effectiveness Analysis of Ticagrelor and Prasugrel for the Treatment of Acute Coronary Syndrome.
Zhao YJ; Khoo AL; Lin L; Teng M; Wu TS; Chan MY; Lim BP
Value Health Reg Issues; 2016 May; 9():22-27. PubMed ID: 27881255
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness analysis of personalized antiplatelet therapy in patients with acute coronary syndrome.
Jiang M; You JH
Pharmacogenomics; 2016 May; 17(7):701-13. PubMed ID: 27167099
[TBL] [Abstract][Full Text] [Related]
18. Direct healthcare costs and cost-effectiveness of acute coronary syndrome secondary prevention with ticagrelor compared to clopidogrel: economic evaluation from the public payer's perspective in Poland based on the PLATO trial results.
Pawęska J; Macioch T; Perkowski P; Budaj A; Niewada M
Kardiol Pol; 2014; 72(9):823-30. PubMed ID: 24846362
[TBL] [Abstract][Full Text] [Related]
19. CYP2C19-guided antiplatelet therapy: a cost-effectiveness analysis of 30-day and 1-year outcomes following percutaneous coronary intervention.
Borse MS; Dong OM; Polasek MJ; Farley JF; Stouffer GA; Lee CR
Pharmacogenomics; 2017 Aug; 18(12):1155-1166. PubMed ID: 28745582
[TBL] [Abstract][Full Text] [Related]
20. The cost effectiveness of genetic testing for CYP2C19 variants to guide thienopyridine treatment in patients with acute coronary syndromes: a New Zealand evaluation.
Panattoni L; Brown PM; Te Ao B; Webster M; Gladding P
Pharmacoeconomics; 2012 Nov; 30(11):1067-84. PubMed ID: 22974536
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
